Authorization and Utilization Review — Facility, Post-Acute, Behavioral Health, and Select Outpatient Services
Customize your policy alerts
Sign up for all Fidelis Care policy alerts
Know when Fidelis Care releases new policies or updates existing guidance.
Monitor payer policy activity
Governs prior authorization, utilization review, and service-specific authorization rules for Fidelis Care Medicaid (and related lines) providers in New York State, including inpatient, outpatient, behavioral health, SUD, transplant, and surgical services.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Exemptions and utilization review triggers
Exemptions from prior authorization and concurrent review apply when ALL listed conditions are met for specific in‑state, in‑network licensed facilities:
Services may be subject to review after day 28 or on discharge; submit LOCADTR and Appendix A per policy.
Facility must notify Fidelis Care within two business days of admission.
Out‑of‑network facilities remain subject to concurrent review throughout admission.
Inpatient admission authorization
Covered when ALL of the following are met:
New fax number for Inpatient ER: 833‑663‑1602.
Behavioral health outpatient authorization exceptions
Covered when service is outpatient behavioral health except the following which require authorization:
See testing request form guidance.
96110 must be billed with diagnosis Z13.41 or Z13.42 and follow Bright Futures/AAP schedule.
Partial Hospitalization Admission Criteria
Partial hospitalization mental health treatment is subject to utilization review and covered only when ONE of the following OMH criteria is met:
Per NYS OMH Best Practice Manual; out‑of‑network facilities are subject to concurrent review throughout admission.
Intensive Outpatient Admission/Concurrent Review Criteria
Intensive outpatient mental health treatment requires authorization beyond initial 7 days and is subject to review when ONE of the following OMH criteria is met:
No prior authorization needed for first 7 service days; additional days require authorization.
TMS Medical Necessity Criteria
Transcranial Magnetic Stimulation (TMS) is covered with authorization when ALL of the following are met:
Authorization required for CPT codes 90867, 90868, 90869; submit requests to Behavioral Health authorization contacts.
Developmental Screening Coverage
Developmental screening (96110) is covered in the first three years of life with the following rules:
Excludes CHP for the no‑authorization rule for 96110; providers must score and document standardized tool data.
Children's Respite / HCBS Criteria
Children's HCBS and short‑term respite services coverage and limits:
Submit Plan of Care and notification before services to avoid claims disruption.
DXA no-authorization exceptions
DXA (77080/77081) is not subject to authorization when ALL of the following age/diagnosis conditions are met:
Requests for other age/diagnosis combinations require authorization.
OB Ultrasound coverage
OB ultrasound rules:
Normal pregnancy diagnosis examples: Z32.01, Z33.1, Z34.00‑Z34.03, etc.; high‑risk diagnosis list exempts authorization.
Therapy services (PT/OT/ST)
PT/OT/ST prior authorization requirements:
If billing codes other than initial evaluation CPT codes are used, an authorization request must be sent to Evolent within 1 business day (outpatient) or 2 business days (home health), or to Fidelis for inpatient settings.
Not covered for Low Back Pain
Services not covered for members with a diagnosis of Low Back Pain:
These services are listed as not covered for Low Back Pain diagnoses.
Out-of-state or out-of-network providers must request prior authorization for outpatient substance use services that in‑network, in‑state OASAS‑licensed providers do not require authorization for. This includes outpatient office visits, therapy or counseling visits, outpatient clinic visits for substance use disorder treatment, intensive outpatient treatment programs, outpatient rehabilitation, and opioid treatment programs; providers located outside New York State or outside Fidelis Care’s network remain subject to authorization and concurrent review requirements.
Certain CLHRS/OLHRS services delivered by designated 29‑I facilities are excluded from Utilization Review; Fidelis Care will not conduct UR on the OLHRS items listed for services delivered by 29‑I facilities. However, when a 29‑I facility provides Children and Family Treatment & Support Services (CFTSS) or Children's Home and Community Based Services (Children's HCBS), those services remain subject to the authorization requirements specified in their respective sections and workflow (e.g., Children's HCBS authorization and notification forms).
The policy lists explicit exclusions and code‑based non‑coverage: HCPCS codes for medications that are not FDA‑approved (for example, J1726) are a benefit exclusion and will be denied when billed. In addition, specific service/code combinations are non‑covered per Appendix and Pharmacy guidance (see Appendix I). Therapeutic service exclusions for certain diagnoses (see Low Back Pain exclusions) are described elsewhere in the policy.
CPT code 20610 (injection, small joint) is designated as non‑covered when billed in combination with hyaluronic acid products listed (e.g., J7318, J7320, J7321, J7322, J7323, J7324, J7325, J7326, J7327, J7328, J7329, J7331, J7332) and an osteoarthritis of the knee diagnosis (specified M17 series codes). Claims with this billing combination will be denied as non‑covered.
For routine (normal) pregnancies, the first 4 OB ultrasounds may be performed without prior authorization. When a member receives five or more OB ultrasounds for a normal pregnancy (diagnosis codes such as Z32.01, Z33.1, Z34.00‑Z34.03, etc.), authorization is required for the fifth and subsequent ultrasounds; OB ultrasounds for high‑risk pregnancy diagnoses listed in the policy do not require authorization.
The policy explicitly lists therapeutic procedures that are not covered for members with a diagnosis of Low Back Pain. These include: prolotherapy; therapeutic facet joint steroid injections in the lumbar and sacral regions (with or without CT fluoroscopic guidance); therapeutic steroid injections into intervertebral discs; and continuous or intermittent traction. Claims for these services when billed with a Low Back Pain diagnosis will be denied as not covered.
Code Tables and Billing Codes
| 96116 | Psychological testing |
| 96121 | Psychological testing |
| 96130 | Neuropsychological testing |
| 96131 | Neuropsychological testing |
| 96132 | Neuropsychological testing |
| 96133 | Neuropsychological testing |
| 96136 | Psychological testing |
| 96137 | Psychological testing |
| 96138 | Psychological testing |
| 96139 | Psychological testing |
| H0040 | Assertive Community Treatment (ACT) |
| H2012 | Continuing Day Treatment / IPRT referenced |
| H2012K | Intensive Psychiatric Rehabilitation Treatment (IPRT) |
| H2017 | Psychosocial Rehabilitation (CORE) |
| H0036 | Community Psychiatric Support and Treatment (CPST) |
| H0038 | Peer Supports / Youth Peer Supports and Family Peer Support Services |
| H2001 | Crisis Intervention |
| H0004 | Other Licensed Practitioner service |
| H2011 | Other Licensed Practitioner service |
| T1001 | Nursing Assessment |
| S5130U1 | Personal Care Level I (housekeeping) |
| T1019U1 | Personal Care Level II per 15 mins |
| T1019U3 | Level II Mutual Case (multiple) |
| T1019U2 | Level II Shared Aide (up to two) |
| T1019U4 | Level II - Hard to Serve |
| T1020 | Live In Level II per diem |
| G0162 | Nursing Supervision |
| T1019U6 | Consumer Direct 1 Client |
| T1019U7 | Consumer Direct 2 Client |
| T1019U6 | Consumer Direct 1 Client |
| T1019U7 | Consumer Direct 2 Client |
| T1019U8 | Consumer Direct 1 Client Enhanced |
| T1019U9 | Consumer Direct 2 Client Enhanced |
| T1020U6 | Consumer Direct Live In 1 Client |
| T1020U7 | Consumer Direct Live In 2 Client |
| Z32.01 | Encounter for pregnancy test and childbirth planning |
| Z33.1 | Pregnant state |
| Z34.00-Z34.03 | Encounter for supervision of normal first pregnancy |
| C9047 | series entry mapping (e.g., caplacizumab-yhdp / J0256 / alpha 1-prot inhib NOS / J0609 / ferric citrate, oral, ESRD on) |
| C9145 | series entry mapping (e.g., aprepitant aponvie inj / J0257 / alpha 1-prot inhib (Glassia) / Dialysis) |
| C9166 | series entry mapping (e.g., secukinumab, intravenous / J0270 / alprostadil (Prostin VR) / J0615 / calcium acetate, oral, ESRD on) |
| C9301 | obecabtagene autoleucel / J0402 / aripiprazole (Abilify asimtufii) / J0691 / lefamulin (Xenleta) |
| C9302 | zanidatamab-hrii inj (Ziihera) / J0491 / anifrolumab-fnia / J0706 / caffeine citrate inj |
| J0129 | abatacept (Orencia) / various alternate mappings |
| J0139 | adalimumab (Humira) / various alternate mappings |
| J0218 | olipudase alfa-rpcp (Xenpozyme) / J0603 / sevelamer carbonate, oral, ESRD on Dialysis (Renagel) / J1072 / testosterone cypionate inj (Azmiro) |
| J1290 | ecallantide (Kalbitor) / J1599 / immune globulin / J2503 |
| J3399 | onasemnogene abeparvovec (Zolgensma) / J7205 and related mappings |
| J7165 | prothrombin complex concentrate (human-lans) / J7214 and related mappings |
| J7181 | factor XIII A-subunit recombinant (Tretten) / J7320 / hyaluronan (Durolane, Genvisc) / J7999 / J8499 / J8510 |
| J9216 | emapalumab/interferon gamma mappings and related Q-codes |
| J9223 | histrelin implant and isatuximab mappings |
| J9227 | ipilimumab (Yervoy) and inotuzumab mappings |
| J9228 | ipilimumab/inotuzumab and related mappings |
| J9229 | melphalan hydrochloride and related mappings |
| J9245 | melphalan hydrochloride and related mappings |
| Q5144 | Q-code with multiple sub-mappings |
| Q5145 | Q-code with multiple sub-mappings |
| Q5146 | Q-code with multiple sub-mappings |
| Q5147 | Q-code with multiple sub-mappings |
| Q5148 | Q-code with multiple sub-mappings |
| Q5149 | Q-code with multiple sub-mappings |
| Q5150 | Q-code with multiple sub-mappings |
| Q5151 | Q-code with multiple sub-mappings |
| Q5152 | Q-code with multiple sub-mappings |
| S0012 | S0012 mappings (butorphanol nasal, peg interferon alfa-2A, etc.) |
| S0017 | S0017 mappings (aminocaproic acid inj, pegylated interferon alfa-2B, etc.) |
| S0021 | S0021 mappings (cefoperazone inj, dilutant for epoprostenol, dispensing services, etc.) |
| S0034 | S0034 mappings (ofloxacin inj, exemestane oral, etc.) |
| S0040 | S0040 mappings (ticarcillin inj, becaplermin gel, etc.) |
| S0074 | S0074 mappings (cefotetan inj, dextroamphetamine oral, etc.) |
| S0078 | S0078 mappings (fosphenytoin inj, calcitriol oral, etc.) |
Prior Authorization, Documentation, and Routing Instructions
Prior Authorization Required for Listed Services
Prior authorization is required for the services and codes listed below. Failure to obtain required prior authorization may result in claim denial or retrospective review. When prior authorization is required, submit requests to the delegated vendor when indicated (Evolent/TurningPoint/other) or to Fidelis Care per the routing instructions in each callout.
- All inpatient admissions require authorization except emergency room stabilization services; post-stabilization inpatient care requires authorization.
- Outpatient surgical procedures enumerated in Sections II–III require prior authorization (see code lists and delegated vendors).
- Certain orthopedic/spinal, ENT, and cardiac surgical procedure prior authorizations have been delegated to Evolent (NIA) or TurningPoint — follow delegated routing for those CPTs.
Psychological/Neuropsychological Testing — Authorization Submission Requirements
Psychological and neuropsychological testing codes require authorization. All requests must be submitted using the Fidelis Psychological/Neuropsychological Testing request form and include clinical documentation supporting test selection and indications.
Developmental Pediatric Testing — Authorization Rules and Documentation
Developmental pediatric testing and screening have specific authorization rules. Code 96112 and 96113 require authorization. CPT 96110 (developmental screening) does not require authorization (except for CHP) but must be billed with the appropriate screening diagnosis and documented per guidance.
- 96112, 96113 — Authorization required.
- 96110 — No authorization required (excluding Child Health Plus). When billed, use diagnosis Z13.41 (autism screen) OR Z13.42 (screening for global developmental delays) and document use of a standardized validated screening tool, scoring, and recommendations.
- Developmental screening frequency: follow Bright Futures/AAP periodicity — ASD screening up to twice in first three years (beginning at 18 months); global developmental delay screening up to once per year in first three years.
TMS Prior Authorization — CPTs 90867-90869
Transcranial Magnetic Stimulation (TMS) is a covered service but requires prior authorization for the listed CPT codes and medical necessity criteria must be met.
- Authorization required for CPT 90867, 90868, 90869.
- Requests may be submitted via email to qhcmbh@fideliscare.org, fax 833-561-0098, or by calling 1-888-FIDELIS and following Behavioral Health prompts (ext. 16072).
- Members must be >18, have FDA-cleared device used per labeled indications, a confirmed diagnosis of major depressive disorder, and failure of appropriate medication and evidence-based psychotherapy trials during the current episode.
DME Prior Authorization — DME/Supplies Routing and MLTC Specifics
Durable medical equipment (DME) and certain supply codes require prior authorization; refer to NYS DME Manual and program-specific routing. MLTC-specific supply codes also require authorization.
- DME coverage and benefit limits follow the Medicaid DME Program Manual: https://www.emedny.org/ProviderManuals/DME/index.aspx.
- Effective 4/1/23 select DME supplies billed by physicians (POS 12/14) were transitioned to NYS Fee-for-Service (NYRx); check the Medical Supply Procedure Codes list for those supplies.
- For MLTC members, the following supply HCPCS require authorization: A4335, A4554, T4521-T4524, T4529, T4530, T4533, T4535, T4537, T4539, T4540, T4543.
- Personal Emergency Response Systems (PERS) and Consumer Directed Personal Assistance Services (CDPAS) require authorization.
- Submit DME authorization requests per Fidelis routing unless otherwise directed in the DME manual or member line of business guidance.
Imaging Prior Authorization — Delegation to Evolent and Specific Rules
Many imaging services require prior authorization. Radiology prior authorization has been delegated to Evolent (NIA) for a broad set of radiology CPTs; certain ultrasounds and DXA/TBS rules and exceptions apply.
- Prior authorization delegated to Evolent (NIA) for radiology services — follow Evolent routing where indicated.
- OB ultrasound rules: first four OB ultrasounds do not require authorization; five or more for a normal pregnancy require authorization. OB ultrasounds for high-risk pregnancies do not require authorization.
- DXA (77080/77081) — no authorization for specified age/diagnosis groups (women >65, men >70, and select age/diagnosis criteria for ages 51–69/51–64); other uses require authorization.
- Therapy services (PT/OT/ST) after the initial evaluation require prior authorization through Evolent (NIA) for home/outpatient settings; home therapy initial evaluations require authorization and inpatient/home timing rules apply (see therapy callout).
Prior Authorization for Imaging/Therapeutic/Pain Management Services and Not Covered Low Back Pain Services
Prior authorization is required for many imaging, therapeutic, and pain management services and for specific procedure codes. Some pain and therapeutic services are not covered for low back pain diagnoses.
- Therapeutic services requiring authorization include phototherapy, hyperbaric oxygen, pain management injections and interventional pain codes (see list).
- Pain management and interventional codes include 20526, 20550-20553, 21073, 27096, 62263-62327, 64400-64530, 64553-64595, 64600-64610, 64618-64640 and interventional codes 63650, 63655, 63661-63664, 63685, 63688, and related device HCPCS.
- Not covered for members with diagnosis of Low Back Pain: prolotherapy; therapeutic facet joint steroid injections in lumbar/sacral regions (with or without CT guidance); therapeutic intradiscal steroid injections; continuous or intermittent traction.
- Topical oxygen and specified other therapeutic services require prior authorization.
Oncology Medication and Appendix I Prior Authorization Routing
Oncology medications and many drug administration/HCPCS (Appendix I) codes require prior authorization and have specific routing. Evolent manages oncology medication prior authorizations for most Medicaid/HARP members; Appendix I requests are routed to Fidelis Pharmacy.
- Oncology medications and supportive agents — prior authorization required via Evolent (https://um.newcenturyhealth.com) for Medicaid Managed Care and HARP medical benefit (excludes Child Health Plus).
- Appendix I lists HCPCS/CPT/J/Q/S/Q99x codes that require prior authorization; submit Appendix I prior authorization requests to Fidelis Pharmacy Team by e-fax 1-844-235-5090 unless excluded per section B.
- Appendix I is distinct from the Evolent oncology program; certain oncology-related requests remain under Evolent — follow section-specific routing instructions.
- HCPCS S codes are benefit exclusions except S0013, S0189, S0190, S0191, S9435; consult Appendix I and pharmacy guidance for S-code handling.
Appendix I — Codes Requiring Prior Authorization (Submission and Denial Risk)
Appendix I enumerates numerous J-, Q-, C-, G-, J7xxx, Q5xxx, Q9xxx, and S-code groups that require prior authorization before billing. These codes must have prior authorization submitted and approved to avoid denial. Appendix I also contains codes that are non-covered when billed with specific diagnoses.
- Appendix I is the authoritative list of medication and drug administration HCPCS/CPT codes that require PA prior to claim submission; examples include numerous J-codes (e.g., J0401, J0641…), Q-codes, C-codes, G0516/G0517, J7xxx series, and many oncology-related J9xxx/J92xx series.
- Some Appendix I HCPCS for medications not FDA-approved (e.g., J1726) are benefit exclusions.
- Certain HCPCS (e.g., J7318–J7333 series) are non-covered when billed with specific musculoskeletal diagnoses (see policy for code/diagnosis pairs).
- Maximum unit edits apply to all HCPCS regardless of PA status; verify units against Fidelis Maximum Units policy.
Documentation for Prior Authorization-Required Codes
For services and codes that require prior authorization, ensure supporting documentation is submitted with the PA request and retain it for claims support. For Appendix I drug administration codes and other PA-required codes, include clinical indication, dosing/units, frequency, and relevant prior treatments.
- Appendix I J- and Q- code administrations require PA submissions to Fidelis Pharmacy via e-fax 1-844-235-5090 unless routed to Evolent per oncology program guidance.
- Include: clinical notes, diagnosis, prior therapy history, proposed dosing/units, expected duration, and site of administration.
- Incomplete documentation or lack of PA may result in claim denial or retrospective medical necessity review.
Therapy Prior Authorization Timing and Routing
Outpatient therapy prior authorization timing and routing: after the initial evaluation, outpatient/home therapy requires prior authorization through Evolent (NIA) with specific submission timeframes; inpatient therapy routing differs.
- Home and outpatient PT/OT/ST (after the initial evaluation) require prior authorization through Evolent (NIA).
- If submitting claims using codes other than designated initial evaluation CPT codes, an authorization request must be sent to Evolent (NIA) within 1 business day for outpatient settings or within 2 business days for the home health setting.
- For therapy services provided in inpatient settings (POS 31 & 32), prior authorization requests are to be faxed to 833-663-1611.
- CPT 92610 and 92611 (specified speech codes) do not require prior authorization.
Home Health and Consumer-Directed Services — Authorization and Documentation
Home health and consumer-directed services require authorization and documentation supporting skilled needs, and certain consumer-directed HCPCS/unit rules apply.
- Home health approvals are based on documented medical need for skilled services.
- Consumer Directed Personal Assistance (CDPAS) and Consumer Direct services require authorization and must be billed using the specified HCPCS (e.g., T1019U6–T1020U7) and unit conventions.
- For Children's HCBS and respite exceeding program limits, submit LPHA attestation and NYS DOH forms (Children's HCBS Authorization and Care Manager Notification) prior to service delivery to avoid claim disruptions. Submit forms to SM_Childrens_HCBS@fideliscare.org or fax 833-663-1604.
OMH and OASAS Notification and Documentation to Avoid Concurrent Review
Providers must follow OMH and OASAS notification and documentation processes to avoid concurrent review during the initial inpatient periods and to ensure proper claims handling.
- OMH licensed inpatient mental health (members <18): facility must notify Fidelis Care of admission and initial treatment plan within two business days using OMH 'Two-Day Notification and Initial Treatment Plan' form; submit by fax 833-561-0094 or email Mental_Health_Admission@fideliscare.org. No concurrent utilization review during first 14 days if requirements met.
- OASAS licensed inpatient SUD: facility must notify Fidelis Care and submit OASAS Appendix A Notification Form and LOCADTR Medical Necessity Tool within two business days to fax 833-663-1608 or LOCADTR@fideliscare.org to avoid concurrent review for the first 28 days. Facilities must provide discharge plan prior to discharge and indicate whether services in the discharge plan are secured/available.
- Facilities must perform daily clinical review and participate in periodic consultation with Fidelis starting near day 14 for SUD and day 14 for OMH to ensure appropriate use of clinical review criteria.
Voicemail Compliance for UM Messages
Utilization Management (UM) voicemail messages containing PHI may be left only if the provider voicemail is HIPAA-compliant. Mailbox greetings must identify owner and organization and state confidentiality and PHI acceptance.
- If voicemail is HIPAA-compliant, UM will leave a detailed message. If not, a generic message requesting callback will be left.
- When attempting UM determinations, Fidelis will make a second direct contact attempt per DOH Reasonable Effort Policy.
Admission Criteria by Setting
acute/sub-acute/SNF admission criteria
Fax for inpatient ER: 833‑663‑1602.
Inpatient SUD admission criteria
Out‑of‑state or out‑of‑network facilities must request prior authorization and are subject to concurrent review throughout admission.
Inpatient mental health admission criteria
Out‑of‑network facilities are subject to concurrent review throughout admission.
partial hospitalization / intensive outpatient admission criteria
Out‑of‑network facilities subject to concurrent review throughout admission.
Adult Day Health Care admission criteria
Continuation beyond transition period is reviewed for medical necessity.
Continued Stay / Ongoing Care Criteria
inpatient continued stay criteria
Facilities must consult with Fidelis Care per SUD and OMH rules.
partial hospitalization / intensive outpatient continued stay criteria
Out‑of‑network facilities are subject to concurrent review throughout admission.
Adult Day Health Care continued stay criteria
Initial assessment up to two visits requires prior authorization for new patients.
Discharge Planning and Criteria
For in‑network, New York State OASAS‑licensed inpatient SUD facilities, the policy requires notification and documentation but does not define additional top‑level discharge criteria as standalone nodes. Facilities must notify Fidelis Care of the admission and initial treatment plan within two business days, perform daily clinical review, periodically consult with Fidelis Care (beginning on or just prior to day 14), and provide a written discharge plan to the member and Fidelis Care prior to discharge indicating whether services in the discharge plan are secured or reasonably available. Inpatient SUD services may be subject to utilization review after day 28 or upon discharge using the LOCADTR clinical review tool.
Children's HCBS and related short‑term Planned and Crisis Respite do not present separate top‑level discharge criteria in the policy inventory. The policy requires submission of the NYS Children's HCBS Authorization and Care Manager Notification Form and any LPHA attestation to support services beyond the annual limits; providers must submit required documentation prior to rendering services to avoid claim processing disruptions and should submit Plan of Care items as specified.
Other discharge items in the facility care sections do not identify additional top‑level discharge criteria in the inventory. Relevant discharge expectations include those for home health/consumer‑directed services and hospice: providers must ensure discharge planning and documentation are completed per the applicable benefit rules (for example, hospice requests for Medicaid members should be submitted to Fidelis Care).
Initial Days and Service Day Limits
Background and Scope
This update restates delegated authorization arrangements and clarifies utilization review during the COVID‑19 era. Key delegation and restatement points include: OASAS‑licensed in‑network inpatient SUD services in New York State are exempt from prior authorization and from concurrent utilization review for the first 28 days when the facility meets notification and documentation requirements (notify within two business days, perform daily clinical review, consult with Fidelis Care near day 14, and provide a written discharge plan prior to discharge). Similarly, OMH‑licensed inpatient mental health facilities have defined notification and documentation workflows to avoid concurrent review for the first 14 days for members under 18. The policy also reiterates that certain prior authorization responsibilities and radiology authorization processes have been delegated (for example, radiology prior authorization delegated to Evolent/NIA) and that providers should follow the specified notification and auth submission procedures.
Definitions and Tools
Coding Notes, Frequency, and Limits
Ensure PA is obtained for listed services and codes before billing
Prior authorization is required for the services and codes listed in the policy; providers must follow the policy's routing and submission instructions to obtain PA prior to service or billing.
- All inpatient admissions require authorization (emergent stabilization excluded).
- Appendix I and sections II–V list numerous CPT/HCPCS/J/Q/S codes that require PA.
Policy Revision History
Musculoskeletal Management Program delegation to Evolent (NIA) for orthopedic and spinal procedure authorization and device review became effective.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.